Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Dow
Johnson and Johnson
Express Scripts
Colorcon

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Lumacaftor

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Lumacaftor: Patents, clinical trial progress, indications

Lumacaftor is an investigational drug.

There have been 33 clinical trials for Lumacaftor. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2018.

The most common disease conditions in clinical trials are Cystic Fibrosis, Fibrosis, and Lung Diseases. The leading clinical trial sponsors are Vertex Pharmaceuticals Incorporated, National Heart, Lung, and Blood Institute (NHLBI), and Nivalis Therapeutics, Inc.

There are ninety-one US patents protecting this investigational drug and eight hundred and seventy-four international patents.

Recent Clinical Trials for Lumacaftor
TitleSponsorPhase
Validation of Respiratory Epithelial Functional Assessment to Predict Clinical Efficacy of Orkambi®.Assistance Publique - Hôpitaux de ParisN/A
Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240University of North CarolinaEarly Phase 1
Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240University of MiamiEarly Phase 1

See all Lumacaftor clinical trials

Clinical Trial Summary for Lumacaftor

Top disease conditions for Lumacaftor
Top clinical trial sponsors for Lumacaftor

See all Lumacaftor clinical trials

US Patents for Lumacaftor

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Lumacaftor   Start Trial Compounds, compositions, and methods for increasing CFTR activity Proteostasis Therapeutics, Inc. (Boston, MA)   Start Trial
Lumacaftor   Start Trial Modulators of ATP-binding cassette transporters Vertex Pharmaceuticals Incorporated (Boston, MA)   Start Trial
Lumacaftor   Start Trial Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof Vertex Pharmaceuticals Incorporated (Boston, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Johnson and Johnson
AstraZeneca
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.